This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Charlotte Teunissen
Amsterdam UMC, Amsterdam, Netherlands

Charlotte Teunissen (full professor in Neurochemistry) aims to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group span the entire spectrum of biomarker development, starting with biomarker identification, followed by assay development and validation, and extensive clinical validation to ultimately implement novel biomarkers in clinical practice. 


She is responsible for the Alzheimer Center Amsterdam body fluid and leads several international biomarker networks, such as the CSF Society and the Alzheimer Association-Global Biomarker Standardization consortium, and the recently founded Coral proteomics consortium. She is the coordinator of the Marie Curie MIRIADE project, aiming to train 15 novel researchers into accelerate dementia biomarker development.


Frank Jessen

University of Cologne, Cologne, Germany

Frank Jessen received his MD degree from the University of Saarland in 1995. After residencies in neuropathology at the University of Düsseldorf, and neurology and psychiatry at the University of Bonn, he was board certified as a psychiatrist and psychotherapist in 2002. He served from 2002-2010 as a consultant psychiatrist and head of clinical Alzheimer’s disease research at the Department of Psychiatry, University of Bonn. In 2010, he was appointed Professor of Clinical Dementia Research and deputy director of the Department of Psychiatry, University of Bonn. In 2015, he was appointed as a Professor of Psychiatry and Psychotherapy and director of the Department of Psychiatry, University of Cologne.  Since 2010, he is an associate researcher and group leader at the German Center of Neurogenerative Diseases (DZNE).


Frank Jessen’s research focusses on prevention, early diagnosis and treatment development in Alzheimer’s disease with expertise in neuropsychology, neuroimaging, epidemiology and genetics. He coordinated national and international multicenter observational studies and clinical trials. He is author of over 550 publication and of over 20 books and book chapters on Alzheimer’s disease.


He is a member of the DZNE clinical board, chairman of the European Alzheimer’s Disease Consortium (EADC) and member the NIA-AA working group on Alzheimer’ s disease criteria. He is the past chairman of the ISTARRT professional interest area on subjective cognitive decline (SCD) and the SCD-initiative (SCD-I). He is the main author of the German national guideline on the diagnosis and treatment of dementia.

Read full bio

Krista L. Lanctôt

University of Toronto, Toronto, Canada

Dr. Krista L. Lanctôt has a PhD in Clinical Pharmacology from the University of Toronto, with additional training in pharmacoepidemiology.  She is currently a Senior Scientist in Geriatric Psychiatry and in the Hurvitz Brain Sciences Program at Sunnybrook Research Institute, Research Co-Director in the Department of Psychiatry at Sunnybrook Health Sciences Centre and the Head of Neuropsychopharmacology Research.  In 2022, she was awarded the Bernick Chair is Geriatric Psychopharmacology. She is also a Full Professor of Psychiatry and Pharmacology/Toxicology, and Vice Chair of Basic and Clinical Sciences in the Department of Psychiatry at the University of Toronto, Toronto, Ontario, Canada.  


Dr. Lanctôt is an active researcher with over 350 published papers, and Editor of the 2021 book “Apathy: Clinical and Neuroscientific Perspectives from Neurology and Psychiatry”.  Her group’s research has focused on optimizing the pharmacotherapy of cognition and neuropsychiatric symptoms associated with dementia and in predementia states.  She currently holds grants as a PI from the Alzheimer’s Drug Discovery Foundation, Alzheimer’s Association US, Weston Brain Institute and Canadian Institutes of Health Research.  She is a full member of the School of Graduate Studies in the Faculty of Medicine, University of Toronto, previous winner of the Faculty of Medicine Graduate Education Award, and has trained more than 35 graduate students.

Read full bio